Immunohistochemical analysis of ras oncogene product p21 in human endometrial carcinoma.
Monoclonal antibody rp-28 directed against the ras gene product p21 has been used to evaluate ras p21 expression in endometrial lesions. Endometrial cancer showed a variable reactivity according to histological type: in well differentiated adenocarcinoma 63% were positive (12/19); in moderately differentiated adenocarcinoma 53% were positive (8/15); in poorly differentiated adenocarcinoma 40% were positive (2/5). The staining intensity of ras p21 seemed to be stronger in the more differentiated types of endometrial carcinoma. In endometrial carcinoma with premenopausal women, 27% were positive (3/11), and with postmenopausal women 71% were positive (20/28). The difference between premenopausal and postmenopausal groups was statistically significant (Mantel-Haenszel procedure, M-H chi 2 = 6.765, P < 0.01). The results suggest the existence of different carcinogenetic mechanisms in these two groups of endometrial cancer.
Yaginuma
Y
Y
Department of Obstetrics and Gynecology, Asahikawa Medical College, Japan.
Fujita
M
M
Saitoh
S
S
Hayakawa
K
K
Kuzumaki
N
N
Ishikawa
M
M
D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000378:metabolism; D007150:Immunohistochemistry; D007889:Leiomyoma / Q000473:pathology; D007890:Leiomyosarcoma / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D015689:Oncogene Protein p21(ras) / Q000276:immunology / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000378:metabolism* / Q000473:pathology
D000911:Antibodies, Monoclonal; D015689:Oncogene Protein p21(ras)